Related by context. All words. (Click for frequent words.) 66 Civacir 66 LymphoStat B TM 66 MOZOBIL 65 Phase Ib IIa 65 VivaGel ™ 65 CCR5 mAb 65 Cloretazine ® 64 Personalized Immunotherapy 64 OvaRex ® MAb 64 initiated Phase Ib 64 non nucleoside inhibitor 64 Phase Ib study 64 Completes Patient Enrollment 64 HuMax TAC 64 Phase 2a clinical trials 64 valopicitabine NM# 64 Oncotype DX colon cancer 64 FOLOTYN ® 64 Daclizumab 63 RenaZorb TM 63 nucleotide analog 63 Clevudine 63 PDE4 inhibitor 63 PD LID 63 SCIB1 63 vidofludimus 63 generation URAT1 inhibitor 63 torezolid phosphate 63 TransVax TM 63 Phase #b/#a clinical 63 maturation inhibitor 63 Aurexis 63 oral ridaforolimus 63 TransVax tm 63 Annamycin 63 INCB# [001] 63 PrevOnco 63 Allovectin 7 63 ALN PCS 63 Panzem R 63 apricitabine ATC 63 SAR# [004] 63 PRECISE trial 62 Vaxfectin 62 refractory chronic lymphocytic 62 PANVAC VF 62 inhaled AAT 62 Initiate Clinical Trial 62 GVAX ® 62 Veronate 62 Achieves Primary Endpoint 62 Vicriviroc 62 Fodosine 62 phase 2a 62 SPRYCEL ® 62 MAGE A3 ASCI 62 Targretin capsules 62 PDX pralatrexate 62 liposomal formulation 62 CCR5 antagonist 62 Mipomersen 62 BiTE R 62 Plicera 62 Dalbavancin 62 trastuzumab DM1 T DM1 62 GALNS 62 interferon gamma 1b 62 Virulizin R 62 Hepatitis C HCV 62 UPLYSO 62 Hedgehog Pathway Inhibitor 62 CRMD# 62 mertansine 62 LEVADEX TM 62 DermaVir Patch 62 DEB# 62 Genasense ® oblimersen 61 Etravirine 61 phase III isavuconazole 61 Phase Ib II 61 YONDELIS 61 PLK1 SNALP 61 generation purine nucleoside 61 Phase 1a clinical 61 Files Investigational 61 Phase 2a clinical 61 Muraglitazar 61 initiate Phase 1b 61 candidate XP# 61 Panzem R NCD 61 MAXY alpha 61 RhuDex ® 61 R#/MEM 61 novel nucleoside analog 61 EOquin TM 61 Dapagliflozin 61 lintuzumab SGN 61 Diamyd R 61 forodesine 61 immunotherapeutic agent 61 VIR# 61 acyclovir Lauriad R 61 R sorafenib tablets 61 XL# anticancer compounds 61 successfully commercialize Iluvien 61 NADiA 61 TBC# 61 Pafuramidine 61 ASCO GI 61 elotuzumab 61 omacetaxine mepesuccinate 61 seliciclib CYC# 61 Eniluracil 61 Phase IIIb clinical 61 fusion inhibitor 61 Hedgehog pathway inhibitor 61 Phase 2a 61 non nucleoside HCV 61 evaluating bafetinib 61 nucleoside analog 61 intranasal formulation 61 phase IIb clinical 61 Therapeutic Vaccine 61 VitiGam 61 Guanilib 61 alvespimycin 61 GVAX R 61 evaluating tivozanib 60 Alvesco R 60 randomized controlled Phase 60 Presents Preclinical 60 Quinamed 60 PEG SN# 60 GLP toxicology studies 60 buccal spray 60 CA9 SCAN 60 compound INCB# 60 PI3K/Akt pathway inhibitor 60 TH# [003] 60 PNP inhibitor 60 Thiarabine 60 HEPLISAV TM 60 PROVENGE sipuleucel T 60 bardoxolone 60 histamine dihydrochloride 60 PSMA ADC 60 XYOTAX TM 60 Canvaxin TM 60 Phase IIb trials 60 including eniluracil ADH 60 human IgG1 monoclonal 60 Initiate Phase 60 SinuNase TM 60 phase IIa clinical 60 topical gel containing 60 Genasense ® 60 miconazole Lauriad 60 SUCCEED trial 60 Tesetaxel 60 lucinactant 60 ongoing Phase 1b 60 IAP inhibitors 60 TransVax 60 2 methoxyestradiol 60 LymphoStat B belimumab 60 Elagolix 60 Aflibercept 60 Solazed 60 Anturol TM 60 registrational 60 ApoB SNALP 60 Elvitegravir 60 Phase lll 60 targeting CD# 60 HCD# [002] 60 phase IIb study 60 pradefovir 60 novel VDA molecule 60 FavId 60 oral proteasome inhibitor 60 Onconase 60 VIVITROL ® 60 TOCOSOL Paclitaxel 60 Initiates Clinical 60 registrational trial 60 Archexin 60 SynCon 60 virus HCV protease inhibitor 60 Biologic License Application BLA 60 EndoTAG TM -1 60 Tezampanel 60 DermaVir 60 Besivance 60 Ocrelizumab 60 Phase 1b trial 60 ORAL Sync 60 Albugon 60 P#X# antagonist 60 evaluating satraplatin 60 reslizumab 60 Androxal TM 60 NDA Submission 59 KRYSTEXXA TM pegloticase 59 AzaSite Plus 59 Tarvacin TM 59 Hsp# Inhibitor 59 BLA filing 59 vosaroxin 59 Phase #b/#a 59 PENNVAX B 59 Viread tenofovir disoproxil fumarate 59 Phase IIB 59 investigational pan BCR 59 ATL# [001] 59 ® pioglitazone HCl 59 Phase IIb clinical trials 59 Phase Ib clinical 59 MT#/MEDI-# 59 highly purified pasteurized 59 telomerase inhibitor drug 59 Phase IIa trial 59 LEVADEX ™ 59 Specifid 59 CIP TRAMADOL ER 59 oral prodrug 59 StaphVAX R 59 RIGScan CR 59 TRX1 59 KRN# 59 Omacetaxine 59 Glufosfamide 59 Targeted Chemotherapy 59 Ecallantide 59 PF # [002] 59 PSN# [002] 59 Phase III Clinical Trial 59 Prostate AdenoCarcinoma Treatment 59 personalized dendritic 59 GW# [003] 59 ChronVac C R 59 Phase #/#a 59 Phase #/#a trial 59 initiate Phase IIb 59 Meets Primary Endpoint 59 Aganocide ® 59 Nipent R 59 Corlux 59 Shigamabs ® 59 ONCONASE R 59 volociximab 59 VCRT 59 PEGylated interferon 59 Announces Poster Presentations 59 telomerase therapeutic 59 OncoVEX 59 rPA anthrax vaccine 59 Unit Dose Budesonide 59 investigational oral hepatitis C 59 HuMax CD4 59 radezolid 59 Hedgehog antagonist 59 Cinryze ™ 59 HCV protease inhibitor 59 TLK# 59 NASDAQ OMER 59 orally administered inhibitor 59 oncolytic virus therapies 59 IL# PE#QQR 59 phase IIa 59 ALN TTR# 59 lumiliximab 59 Camvia 59 CD# CEA 59 Phase IIb III 59 celgosivir 59 huN# DM1 59 valtorcitabine 59 BRILINTA 59 IV APAP 59 Pivotal Phase III 59 Saforis 59 GRNVAC1 59 Regeneron Pharma 59 Cleviprex TM clevidipine 59 Glybera 59 OvaRex R 59 Cloretazine 59 Phase IIb Trial 59 HCV polymerase 59 UVIDEM 59 ITAX 59 EGS# 59 huC# DM4 59 Pirfenidone 59 Phase 2b Clinical Trial 59 Tipranavir 59 ARISE Phase III 59 Initiates Enrollment 59 selective androgen receptor modulator 59 Protease Inhibitor 59 Fast Track Status 59 histone deacetylase HDAC inhibitor 59 deforolimus 59 Retacrit 59 Tanespimycin 59 preclinical pharmacokinetic 59 Empatic ™ 59 Phase 2a Trial 59 SNT-MC#/idebenone 59 Phase #b/#a trial 59 tiapamil 59 phase IIb 59 Vitaxin 59 BARACLUDE R 59 LHRH antagonist 59 Tocosol Paclitaxel 59 HepeX B 59 generation NNRTI 59 investigational humanized monoclonal antibody 58 Multiple Ascending Dose 58 HuMax 58 delivery polymer matrix 58 proteasome inhibitor 58 Xelox 58 Loramyc TM 58 tramiprosate Alzhemed TM 58 Apoptone 58 IMA# 58 Huntexil 58 lorvotuzumab mertansine 58 Phase 2a Study 58 initiate Phase Ib 58 DDP# 58 Randomized Phase 58 Oracea TM 58 Urocidin TM 58 Phase IIa trials 58 Maribavir 58 Nexavar ® 58 forodesine hydrochloride 58 Kamada AAT 58 RH1 58 Actimmune ® 58 Phase 1b clinical 58 ORENCIA ® 58 ALN TTR 58 radiation sensitizer 58 RECOTHROM R 58 sitaxsentan 58 Drug Candidate 58 methylnaltrexone bromide 58 Idera Pharma 58 lipid nanoparticle 58 OncoVEX GM CSF 58 refractory APL 58 AMPAKINE CX# 58 Trofex 58 Begins Dosing 58 compound KOS 58 hoFH 58 fidaxomicin Phase 58 Silodosin 58 oral nucleoside analogue 58 phase IIb trial 58 elvucitabine 58 BRIM3 58 HQK 58 ularitide 58 MAA submission 58 PrevOnco ™ 58 Vectibix panitumumab 58 Multimeric 58 Tarceva TM 58 Soliris TM eculizumab 58 Aganocide 58 ARIKACE ™ 58 Surfaxin LS 58 Initiates Phase II 58 HGS ETR2 58 Raptiva ® 58 Factor VIIa 58 Velcade bortezomib 58 polymerase inhibitor 58 Locteron ® 58 oral salmon calcitonin 58 Troxatyl TM 58 Oral Calcitonin 58 ENDEAVOR III 58 Vaxfectin R formulated 58 Phase IIa clinical trials 58 Therapeutic Competitors companiesandmarkets.com adEgemonye 58 Tamibarotene 58 Bicifadine 58 anti CD3 monoclonal 58 Romiplostim 58 Troxatyl 58 AEG# 58 Shigamabs R 58 initiate Phase 2b 58 antisense drug 58 Safinamide 58 personalized cellular immunotherapy 58 Phase III Clinical Trials 58 Moxifloxacin 58 XOMA 3AB 58 HDL Mimetic Peptide 58 eniluracil 58 Forodesine HCl 58 pharmacokinetic PK study 58 Bremelanotide 58 Files IND 58 amrubicin 58 Pegloticase 58 BRIM2 58 PHX# 58 Nexavar sorafenib 58 Vaxfectin ® 58 octreotide implant 58 LE SN# 58 Evoltra ® 58 novel histone deacetylase 58 small molecule Hedgehog 58 multicenter Phase II 58 rALLy trial 58 JAK2 inhibitor 58 topically applied SEPA 58 nonclinical studies 58 R lenalidomide 58 AERx iDMS 58 Phase IIA 58 GLP1 INT TM 58 ChronVac C 58 Clinical Trial Results 58 lixivaptan 58 Xanafide 58 AAG geldanamycin analog 58 NeuroSTAT ® 58 metastatic castration resistant 58 Panzem 58 SinuNase ™ 58 Zirgan 58 Curaxin CBLC# 58 Somatuline Depot 58 HDL Selective Delipidation 58 Argatroban 58 Traficet EN 58 Immunotherapeutic 58 Agenerase 58 Phase IIa clinical 58 Tyzeka Sebivo 58 Premarket Approval Application 58 Systemic Delivery 58 Allovectin 7 R 58 Tekturna Rasilez 58 ruxolitinib 58 Lenocta 58 JAK inhibitor 58 RDEA# 58 octreotide acetate 58 confirmatory clinical 58 ImmuKnow R 58 drug eluting coronary stent 58 TRISENOX ® 58 oxymorphone ER 58 WX UK1 58 Integrase Inhibitor 58 Febuxostat 58 MAXY G# 57 TELINTRA R 57 anticancer compound 57 SYCREST 57 Xcellerated T Cells 57 CELVAPAN H#N# 57 ELACYT 57 Somatuline R Autogel R 57 Abiraterone acetate 57 treatment naive genotype 57 QNEXA ® 57 Phase 2b Trial 57 Phase III ADT 57 YONDELIS R 57 Vidaza R 57 ONGLYZA ™ 57 DR Cysteamine 57 EP #R 57 Xcytrin R 57 RhuDex TM 57 Vertex hepatitis C 57 rxRNA 57 trodusquemine 57 Virulizin ® 57 MKC# MT 57 Relivar 57 oral FTY# 57 miconazole Lauriad ® 57 BCR ABL inhibitor 57 NADiA ProsVue 57 NXL# 57 Phase III Pivotal 57 Alexza Pharma 57 Stimuvax R 57 REMINYL ® 57 Keryx Biopharma 57 Protexia ® 57 assessing T DM1 57 LEAPS TM 57 liprotamase 57 HDAC Inhibitor 57 Alfacell proprietary ribonuclease 57 ABILIFY ® 57 CTAP# Capsules 57 JOULFERON 57 Valortim TM 57 Inc. Amex SYI 57 Junovan TM 57 product candidate Lpathomab 57 Temsirolimus 57 DPX Survivac 57 Amrubicin 57 phase IIb III 57 Spiegelmer ® 57 preclinical efficacy 57 Lixisenatide 57 Kahalalide F 57 MBRX 57 Cloretazine R VNP#M 57 H#N# VLP vaccine 57 prostone 57 Bayer HealthCare Onyx Pharmaceuticals 57 immunotherapeutic vaccine 57 Emezine 57 NV1FGF 57 TYZEKA 57 BLA submission 57 Phase IIb clinical 57 XL# SAR# 57 thetreatment 57 oral Hsp# inhibitor 57 CAELYX 57 Valopicitabine 57 bortezomib Velcade 57 Diamyd ® 57 Genz # 57 Diabetic Macular Edema 57 tolevamer 57 integrase inhibitor 57 Inc. NASDAQ BPAX 57 Vivecon 57 rALLy 57 SNT MC# 57 Phase 1b clinical trials 57 bioequivalency 57 acyclovir Lauriad ® 57 TOCOSOL Camptothecin 57 TAXUS Element Stent System 57 ferric citrate 57 rasagiline tablets 57 budesonide foam 57 antibody MAb 57 BrachySil TM 57 cystinosis patients 57 Onco TCS 57 Vaxfectin R adjuvant 57 eligen 57 ZALBIN 57 IIa trial 57 Bezielle 57 ELND# 57 aldehyde dehydrogenase ALDH2 deficiency 57 Varespladib 57 dacetuzumab 57 Nasdaq PGNX today 57 RELOVAIR ™ 57 ZEVALIN ® 57 ORENCIA R 57 reduce serum phosphate 57 T Pred 57 molecular imaging radiopharmaceutical 57 Shigamabs 57 balsalazide tablet 57 Rescula 57 sNDA submission 57 ChemGenex Pharmaceuticals Limited 57 Amikacin Inhale 57 beta 1a 57 Auxilium Pharma 57 Phase 1b 57 Cimzia TM 57 OMAPRO ™ 57 generation PNP inhibitor 57 Deferiprone 57 sargramostim 57 OMP #M# 57 QLT# 57 oral taxane 57 Iluvien TM 57 Ganciclovir 57 NS5A inhibitor 57 Japanese Encephalitis Vaccine 57 R#/MEM # 57 Proquin XR 57 midstage trials 57 boosted protease inhibitor 57 AERx ® 57 ospemifene 57 oral renin inhibitor 57 Submits Response 57 AZILECT ® 57 AE# vaccine 57 Technosphere Insulin 57 Ramelteon 57 targeted radiotherapeutic 57 Alferon N 57 LEP ETU 57 GTC recombinant form 57 HGS ETR1 57 Tasigna nilotinib 57 Anavex #-# 57 Onalta 57 MGN# 57 #th Annual Interscience 57 immune modulatory 57 Radezolid 57 HuMax CD#b 57 next generation URAT1 57 IND CTA 57 Nasdaq VRTX 57 Nalmefene 57 EmbraceAC 57 omega interferon 57 CIP ISOTRETINOIN 57 class anticancer quinolone 57 Prestara 57 MERLIN TIMI 57 Aryplase 57 Dacogen injection 57 orally dosed 57 KNS # 57 ganetespib 57 Marketing Authorisation Application 57 Aztreonam 57 entitled Synergistic 57 MT# MEDI 57 MVA BN 57 LungAlert TM 57 AKT inhibitor 57 HIV integrase inhibitor 57 Pivotal Phase 57 Bosutinib 57 Onalta ™ 57 EDEMA3 57 phase Ib 57 Harry Palmin President 57 vivo preclinical 57 QNEXA 57 ABL inhibitor 57 PEG IFN 57 docetaxel Taxotere R 57 BrachySil 57 IMiDs ® 57 Confirmatory 57 metastatic hormone refractory 57 TMC# [002] 57 hyaluronidase enzyme 57 TRO# 57 oxybutynin ATD TM 57 Oral Fluid 57 pharmacodynamic properties 57 miconazole Lauriad R 57 Japanese Encephalitis vaccine 57 Clolar ® 57 ACUROX 57 NASDAQ AVNR 57 Actemra tocilizumab 57 docetaxel Taxotere ® 57 Ciclesonide 57 Epratuzumab 57 Phase III Trial 57 subcutaneous formulation 57 discontinued Viread 57 Ampakine 56 dirucotide 56 Arzerra ofatumumab 56 Kissei Pharmaceutical 56 Zenvia Phase III 56 NYSE Amex PBTH 56 LibiGel ® 56 Intercell AG VSE ICLL 56 delta opioid receptor 56 NitroMist TM 56 ZFP Therapeutic 56 Enhanze Technology 56 INTERCEPT red 56 recombinant biopharmaceutical 56 Dacogen TM 56 Vitrasert R 56 trastuzumab DM1 56 IND Filing 56 Insegia 56 MKC# 56 Marketing Authorisation Application MAA 56 NASDAQ CXSP announced 56 acetonide FA 56 PIX# trial 56 MEND CABG II 56 DB# [003] 56 ACAPODENE 56 THALOMID 56 oral methylnaltrexone 56 Initiates Clinical Trial 56 IV Busulfex 56 Telatinib 56 DXL# 56 Vaxfectin R 56 Lovaza TM 56 intravenous AAT 56 INCB# [002] 56 Combination REOLYSIN R 56 Phase IIa proof 56 autologous cellular immunotherapy 56 dasatinib Sprycel ® 56 S#.# [006] 56 GA GCB 56 midstage clinical 56 methylnaltrexone 56 rALLy clinical trial 56 Phenoptin 56 maribavir 56 Tengion Neo Urinary Conduit 56 Arzerra TM 56 severe hypercholesterolemia 56 Gleevec imatinib mesylate 56 Allovectin 7 r 56 HuMax EGFr 56 FDA Approvable Letter 56 Omigard 56 PRTX 56 Laquinimod 56 glucokinase activator 56 novel oral anticoagulant 56 zanolimumab 56 multiple myeloma MM 56 BEMA TM Fentanyl 56 APTIMA HPV assay 56 dosing cohort 56 Soliris eculizumab 56 CDP# 56 Nanobody 56 Dose Escalation 56 Co Receptor Tropism 56 AASLD Meeting 56 application sNDA 56 ThermoDox ® clinical 56 IND submission 56 PN# [001] 56 Proellex TM 56 vinflunine 56 Phase Ib clinical trials 56 epoetin zeta 56 Phase 2a trial 56 Panzem ® 56 NEUGENE R 56 evaluating satraplatin plus 56 EOquin 56 PREOS R 56 induced macular edema 56 AdhTAP 56 IMC #B 56 ATG Fresenius S 56 Arikace 56 Locteron exclusively 56 orBec 56 adecatumumab MT# 56 nalbuphine ER 56 indiplon capsules 56 Ceplene histamine dihydrochloride 56 IMiD 56 Angiocept 56 evaluating Actimmune 56 synDNA TM 56 budesonide MMX Phase III 56 Tykerb lapatinib 56 MyVax R 56 Ultrafast Insulin 56 IDX# 56 AZILECT R 56 Alzhemed TM 56 Hematide TM 56 Qutenza TM 56 Phase III randomized controlled 56 Granulocyte Colony Stimulating Factor 56 Oral NKTR 56 Prodarsan R 56 Demonstrates Positive 56 Receives Orphan Drug Designation 56 Initiated Phase 56 NASDAQ ISTA 56 Anidulafungin 56 RSD# 56 intravenous acetaminophen 56 Submits NDA 56 ILUVIEN ® 56 Ixabepilone 56 Ambrisentan 56 SparVax TM 56 trastuzumab emtansine T DM1 56 candidate REP# 56 Pulmonary Arterial Hypertension 56 HGS ETR1 mapatumumab 56 investigational protease inhibitor 56 BLP# Liposome Vaccine 56 Investigational Oral 56 StemEx R 56 ThGRF 56 CEQ# 56 Prulifloxacin 56 cathepsin K inhibitor 56 AQ4N 56 Rasilez HCT 56 GSK# [002] 56 entinostat 56 NasdaqGM SPPI 56 HspE7 56 Abacavir 56 Levoleucovorin 56 multi kinase inhibitor 56 alfa 2a 56 EndoTAG TM 56 vinorelbine tartrate 56 Iluvien ® 56 FDA Accepts 56 fluvoxamine maleate 56 Behcet uveitis 56 PDE# inhibitors 56 non porcine pancreatic 56 RoACTEMRA 56 EGRIFTA TM 56 cancer neuroendocrine tumor 56 E1 INT TM 56 Biomarker Study 56 delafloxacin 56 ImmunoCellular Therapeutics 56 JAK1 56 dose escalation Phase 56 Firdapse 56 COMBIVIR 56 TREANDA 56 lomitapide 56 rindopepimut 56 Deforolimus 56 Cimzia ® certolizumab pegol 56 Granted Orphan Drug 56 plus Copegus 56 incyclinide 56 Kosan dependence 56 SNALP technology 56 Phase IIb Clinical Trial 56 RhuDex 56 Phase III confirmatory 56 custirsen 56 TKM ApoB 56 PLAVIX ® 56 SynCon TM 56 gallium containing 56 PRX # 56 Late Breaker 56 GAMMAGARD 56 Nasdaq REGN 56 mitogen activated ERK kinase 56 Urocidin 56 Virulizin 56 Capesaris 56 oral rivaroxaban 56 BioGlue R 56 sodium thiosulfate STS 56 Glybera R 56 USL# 56 treatment naïve genotype 56 Phase 2b clinical trials 56 OMS#HP 56 Inc. OTCBB SYBD 56 investigational antiplatelet agent 56 Inhalation Solution 56 MAXY VII 56 Lenocta TM 56 Maxy G# 56 pediatric acute lymphoblastic 56 Solorel 56 NGSX 56 BENLYSTA ® 56 ALN HPN 56 Phase 2b monotherapy 56 Afatinib 56 Empatic TM 56 cysteamine bitartrate 56 Fx #A 56 Demonstrates Significant 56 Alemtuzumab 56 Inc. OTCBB ALRX 55 BiTE 55 Genta Incorporated OTCBB GETA 55 alemtuzumab MS 55 Ixempra 55 CINTREDEKIN BESUDOTOX 55 SIR Spheres 55 Vernakalant 55 Altastaph 55 OTCQX QRXPY 55 Pemetrexed 55 PentaStaph 55 treat chronic sinusitis 55 Posiphen 55 sorafenib Nexavar 55 Alocrest 55 nephropathic cystinosis 55 VELCADE melphalan 55 Diabetic Macular Edema DME 55 compound PMX # 55 Phase 2b clinical 55 Aplidin R 55 investigational hepatitis B 55 VEGF inhibitor 55 Preclinical Study 55 oral picoplatin 55 Neo Bladder Augment 55 PEGylated Fab fragment 55 Certican 55 Sanctura XR 55 Myocet 55 tubulin inhibitor 55 Degarelix 55 Orphan Status 55 ATryn R 55 Ceflatonin 55 NuroPro R 55 nitric oxide donating prostaglandin 55 Polymer Microspheres 55 elacytarabine 55 Testosterone MDTS ® 55 INSPIRE Trial Phase III 55 Firazyr 55 StemEx 55 Pivotal Study 55 CVac 55 Aurora Kinase 55 NASDAQ DYAX 55 Genasense R 55 TELINTRA 55 CHAMPION PCI 55 theranostic 55 rilonacept 55 Catena ® 55 HCl capsules 55 Tesmilifene 55 inhaled formulation 55 Rigel R# 55 ATryn ® 55 CAPHOSOL R 55 ZFP Therapeutics 55 Tasimelteon 55 vapreotide acetate 55 includes TOLAMBA TM 55 Solasia 55 Azedra 55 investigational monoclonal antibody 55 LEUKINE 55 AVASTIN 55 DCCR 55 PS# [001] 55 CYT# potent vascular disrupting 55 Successfully Completes Phase 55 memantine HCl 55 dopamine partial agonist 55 TNFerade ™ 55 Nivestim 55 OvaRex MAb 55 confirmatory Phase 3 55 Pertuzumab 55 amifampridine phosphate 55 Squalamine 55 Omapro 55 BAL# [002] 55 OMAPRO 55 synthetic retinoid 55 hypoxia activated prodrug 55 generation antisense inhibitor 55 Amplimexon 55 FASLODEX 55 selective S#P# receptor agonist 55 THR beta agonist 55 PHASE III 55 Zalbin 55 NUEDEXTA ™ 55 Teysuno 55 tramiprosate ALZHEMED TM 55 registrational studies 55 Severe Sepsis 55 PEG PAL 55 Hormone Refractory Prostate Cancer